Ipsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
Guido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
Novo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.
UK specialty pharma Pharmanovia has licensed senaparib, IMPACT Therapeutics’ oral PARP1/2 inhibitor, across 66 countries in a deal worth up to €423.5 million.
London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments.
Sanofi has discontinued development of itepekimab and balinatunfib after disappointing clinical results, ending ongoing programmes across respiratory and inflammatory diseases.
On July 23, Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended the CETP inhibitor obicetrapib for approval after a string of big-name Phase 3 failures over the past two decades. The European Commission’s final approval is expected in the second half of the year.
GSK has announced plans to shut its UK R&D headquarters in Stevenage, UK, moving operations north to a new site in Cambridge, while also announcing a company-wide programme to reduce annual costs by £1.9 billion (€2.2 billion).
Berlin-based Pentixapharm Holding AG has raised about €20.4 million to fund a pivotal Phase 3 trial of its PET diagnostic PentixaFor and advance its CXCR4-targeted theranostics pipeline.